Nanosphere, Inc. (Nasdaq:NSPH), a company enhancing medicine through targeted molecular diagnostics, announced that it has been selected by HealthTrust as a provider of multi-target molecular diagnostic tests for the nearly 1,400 acute care facilities that are part of the HealthTrust membership. Nanosphere, Inc. (NASDAQ:NSPH) weekly performance is 21.17%. On last trading day company shares ended up $1.57. Analysts mean target price for the company is $3.25. Nanosphere, Inc. (NASDAQ:NSPH) distance from 50-day simple moving average is 3.22%.
Agile Therapeutics, Inc., (NASDAQ: AGRX), a women’s health specialty pharmaceutical company focused on the development and commercialization of new prescription contraceptive products, announced that patent U.S. 8,747,888 (‘888 Patent), was issued by the U.S. Patent and Trademark Office on June 10, 2014. The patent is a continuation of its prior patent US 8,246,978 and is intended to provide additional patent protection covering its contraceptive patch, Twirla™ ethinyl estradiol and levonorgestrel transdermal system. Agile Therapeutics Inc (NASDAQ:AGRX) shares advanced 10.33% in last trading session and ended the day on $10.33. AGRX its return on assets is -177.60%.
CEL-SCI Corp. (AMEX: CVM) announced that the United Kingdom’s Medicines and Healthcare Products Regulatory Agency (MHRA) has granted regulatory approval to begin the Company’s Phase III Head and Neck Cancer clinical trial of its investigational cancer immunotherapy treatment Multikine* (Leukocyte Interleukin, Injection) in the United Kingdom (UK). The UK becomes the 13th country to join the trial. Several hospitals and medical clinics in the UK are expected to participate in the Phase III trial for the treatment of head and neck cancer. CEL-SCI Corporation (NYSEMKT:CVM) shares moved up 5.93% in last trading session and was closed at $1.25, while trading in range of $1.14-$1.27. CEL-SCI Corporation (NYSEMKT:CVM) year to date performance is 111.86%.
NeoGenomics, Inc. (NASDAQ:NEO), a provider of cancer-focused genetic testing services, announced that it raised its second quarter revenue guidance, but reaffirmed its quarterly earnings per share guidance. NeoGenomics, Inc. (NASDAQ:NEO) ended the last trading day at $3.33. Company weekly volatility is calculated as 5.85% and price to cash ratio as 30.63. NeoGenomics, Inc. (NASDAQ:NEO) showed a positive weekly performance of 2.15%.